Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study

Inclusion Criteria: * Steroid refractory lupus nephritis * more than 10mg of steroid failed to control disease activity * patients who failed to reduce the amount of steroid * patients who couldn't increase the amount of steroid due to side effects Exclusion Criteria: * Patients who started the immunosuppressant therapy or increased the amount of immunosuppressant within 12 weeks prior to test drug administration * Patients who received cyclophosphamide puls within 24 weeks prior to test drug administration * CNS( Central Nerve System) Lupus patients * hepatic failure patients * Serum creatinine ≧1.5mg/dL